Rare-Disease Biotech PTC Is Surging — And One Fund Just Raised Its Bet. Should You?

San Diego-based Tang Capital Management reported a $38.3 million increase in its stake in PTC Therapeutics (NASDAQ:PTCT) as of September 30, according to its latest SEC filing.Tang Capital disclosed in its November 14 Form 13-F filing that it increased its position in PTC Therapeutics (NASDAQ:PTCT) by 400,000 shares over the prior quarter. The fund’s holding rose to 1.5 million shares with a reported value of $92.1 million as of September 30. The quarter’s net position change in PTCT was $38.3 million.The buy helped raise PTCT to 3.5% of Tang's nearly $2.6 billion in reportable U.S. equity AUM, making it the fund’s fourth-largest holding.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool